Predictive effect of S100A12 and sRAGE on the occurrence of severe acute pancreatitis

Abstract

Introduction

New biomarkers are required for early identification for SAP characterized by high mortality. We aim to testify if serum level of S100A12 and its receptor soluble receptor for advanced glycation end products (sRAGE) could predicted the development of SAP.

Method

We conducted an observational clinical non-interventional pilot study.

74 acute pancreatitis (AP) patients were subgrouped into mild (MAP, n = 22), moderate (MSAP, n = 30) and severe (SAP, n = 22) acute pancreatitis. Blood samples were collected at admission for testing S100A12 and sRAGE. 28 healthy people served as control. The value of Acute Physiology and Chronic Health Evaluation II scores (APACHE II), Balthazar computed tomography severity index (CTSI) and serum level of C-reactive protein (CRP) were collected at admission.

Results

S100A12 and sRAGE level in SAP patient were significantly higher than the ones in control, MAP and MSAP patients. The ROC curve demonstrated the predictive ability of S100A12 (sensitivity = 0.90, specificity = 0.80, area under the curve [AUC] = 0.90) and sRAGE (sensitivity = 0.58, specificity = 1.00, AUC = 0.83). S100A12 and sRAGE was separately correlated with APACHE II and CTSI but not CRP. Combination of new and traditional biomarkers shows more predictive accuracy than traditional biomarkers alone. Specifically, we found S100A12 and sRAGE positively correlated with the type of organ failure (respiratory and renal) and distinguished the transient from persistent organ failure at admission.

Conclusions

Serum level of S100A12 and sRAGE might be used as efficient biomarkers for early identification of SAP.

from #Esophageal Cancer via a.lsfakia on Inoreader http://ift.tt/1Xk3WeP
via IFTTT